High-Dose Daptomycin Therapy for Staphylococcal Endocarditis and When to Apply It

[1]  S. Cosgrove,et al.  A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. , 2013, The Journal of antimicrobial chemotherapy.

[2]  M. Hannan,et al.  High-Dose Daptomycin Therapy for Left-Sided Infective Endocarditis: a Prospective Study from the International Collaboration on Endocarditis , 2013, Antimicrobial Agents and Chemotherapy.

[3]  A. Tomasz,et al.  Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus. , 2013, The Journal of infectious diseases.

[4]  D. Goff,et al.  Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection , 2013, Antimicrobial Agents and Chemotherapy.

[5]  S. Cosgrove,et al.  Multicenter Study of High-Dose Daptomycin for Treatment of Enterococcal Infections , 2013, Antimicrobial Agents and Chemotherapy.

[6]  R. Kullar,et al.  Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  D. Himmelstein,et al.  Infective Endocarditis in the U.S., 1998–2009: A Nationwide Study , 2013, PloS one.

[8]  P. Di Carlo,et al.  High dose of trimethoprim-sulfamethoxazole and daptomycin as a therapeutic option for MRSA endocarditis with large vegetation complicated by embolic stroke: a case report and literature review. , 2013, Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive.

[9]  Arjun Srinivasan,et al.  Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010 , 2013, Infection Control & Hospital Epidemiology.

[10]  A. Rastogi,et al.  Multicenter Evaluation of the Clinical Outcomes of Daptomycin with and without Concomitant β-Lactams in Patients with Staphylococcus aureus Bacteremia and Mild to Moderate Renal Impairment , 2012, Antimicrobial Agents and Chemotherapy.

[11]  M. Rybak,et al.  Evaluation of the Novel Combination of High-Dose Daptomycin plus Trimethoprim-Sulfamethoxazole against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Using an In Vitro Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations , 2012, Antimicrobial Agents and Chemotherapy.

[12]  I. Byren,et al.  Randomized Controlled Trial of the Safety and Efficacy of Daptomycin versus Standard-of-Care Therapy for Management of Patients with Osteomyelitis Associated with Prosthetic Devices Undergoing Two-Stage Revision Arthroplasty , 2012, Antimicrobial Agents and Chemotherapy.

[13]  L. Avery,et al.  Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus Vertebral Osteomyelitis Cases Complicated by Bacteremia Treated with High-Dose Daptomycin and Trimethoprim-Sulfamethoxazole , 2012, Antimicrobial Agents and Chemotherapy.

[14]  J. Pogliano,et al.  Daptomycin-Mediated Reorganization of Membrane Architecture Causes Mislocalization of Essential Cell Division Proteins , 2012, Journal of bacteriology.

[15]  J. Miro,et al.  High-Dose Daptomycin plus Fosfomycin Is Safe and Effective in Treating Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Endocarditis , 2012, Antimicrobial Agents and Chemotherapy.

[16]  F. Agrusta,et al.  High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  S. Richter,et al.  Detection of Staphylococcus aureus Isolates with Heterogeneous Intermediate-Level Resistance to Vancomycin in the United States , 2011, Journal of Clinical Microbiology.

[18]  S. Cosgrove,et al.  High‐Dose Daptomycin for Treatment of Complicated Gram‐Positive Infections: A Large, Multicenter, Retrospective Study , 2011, Pharmacotherapy.

[19]  S. Kuo,et al.  High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: Case report , 2011, BMC infectious diseases.

[20]  D. Hoban,et al.  Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009. , 2011, International journal of antimicrobial agents.

[21]  M. Bassetti,et al.  High-dose daptomycin in documented Staphylococcus aureus infections. , 2010, International journal of antimicrobial agents.

[22]  R. H. Baltz,et al.  Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  Paul D. R. Johnson,et al.  Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications , 2010, Clinical Microbiology Reviews.

[24]  F. D. De Rosa,et al.  Early experience with high-dosage daptomycin for prosthetic infections. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  Ronald N. Jones,et al.  Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals. , 2009, The Journal of antimicrobial chemotherapy.

[26]  C. Woods,et al.  Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. , 2009, The Journal of infectious diseases.

[27]  D. Levine,et al.  Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  C. Urban,et al.  Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  K. Lamp,et al.  Safety and Clinical Outcomes when Utilizing High-Dose (≥8 mg/kg) Daptomycin Therapy , 2009, The Annals of pharmacotherapy.

[30]  Andrew Wang,et al.  Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. , 2009, Archives of internal medicine.

[31]  B. Diep,et al.  Relationship between Susceptibility to Daptomycin In Vitro and Activity In Vivo in a Rabbit Model of Aortic Valve Endocarditis , 2009, Antimicrobial Agents and Chemotherapy.

[32]  Ronald N. Jones,et al.  Characterization of Vancomycin-Heteroresistant Staphylococcus aureus from the Metropolitan Area of Detroit, Michigan, over a 22-Year Period (1986 to 2007) , 2008, Journal of Clinical Microbiology.

[33]  D. Levine.  Clinical experience with daptomycin: bacteraemia and endocarditis. , 2008, The Journal of antimicrobial chemotherapy.

[34]  A. Hidrón,et al.  Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007 , 2008, Infection Control & Hospital Epidemiology.

[35]  K. Lindfield,et al.  A pilot study of high‐dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram‐positive bacteria , 2008, International journal of clinical practice.

[36]  Ronald N. Jones,et al.  Characterization of Vancomycin-Heteroresistant Staphylococcus aureus from the Metropolitan Area of Detroit, Michigan, over a 22-Year Period (1986 to 2007) , 2008, Journal of Clinical Microbiology.

[37]  M. Rybak,et al.  Evaluation of Daptomycin Pharmacodynamics and Resistance at Various Dosage Regimens against Staphylococcus aureus Isolates with Reduced Susceptibilities to Daptomycin in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations , 2008, Antimicrobial Agents and Chemotherapy.

[38]  Warren E. Rose,et al.  Daptomycin Activity against Staphylococcus aureus following Vancomycin Exposure in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations , 2007, Antimicrobial Agents and Chemotherapy.

[39]  Alexander Tomasz,et al.  Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing , 2007, Proceedings of the National Academy of Sciences.

[40]  S. Yankelev,et al.  Pharmacokinetics and Tolerability of Daptomycin at Doses up to 12 Milligrams per Kilogram of Body Weight Once Daily in Healthy Volunteers , 2006, Antimicrobial Agents and Chemotherapy.

[41]  B. Cunha,et al.  Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: Cure with prolonged/high-dose daptomycin without toxicity. , 2006, Heart & lung : the journal of critical care.

[42]  G. Eliopoulos,et al.  Induction of Daptomycin Heterogeneous Susceptibility in Staphylococcus aureus by Exposure to Vancomycin , 2006, Antimicrobial Agents and Chemotherapy.

[43]  M. Rybak,et al.  Impact of High-Inoculum Staphylococcus aureus on the Activities of Nafcillin, Vancomycin, Linezolid, and Daptomycin, Alone and in Combination with Gentamicin, in an In Vitro Pharmacodynamic Model , 2004, Antimicrobial Agents and Chemotherapy.

[44]  M. Rybak,et al.  Daptomycin – a novel antibiotic against Gram-positive pathogens , 2004, Expert opinion on pharmacotherapy.

[45]  M. Rybak,et al.  Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. , 2003, Diagnostic microbiology and infectious disease.

[46]  Patricia F Triplett,et al.  A Prospective Multicenter Study of Staphylococcus aureus Bacteremia: Incidence of Endocarditis, Risk Factors for Mortality, and Clinical Impact of Methicillin Resistance , 2003, Medicine.

[47]  M. Rybak,et al.  Daptomycin Dose-Effect Relationship against Resistant Gram-Positive Organisms , 2003, Antimicrobial Agents and Chemotherapy.

[48]  R. Arbeit,et al.  Daptomycin Pharmacokinetics and Safety following Administration of Escalating Doses Once Daily to Healthy Subjects , 2003, Antimicrobial Agents and Chemotherapy.

[49]  G. Pugliese,et al.  Biofilms: Survival Mechanisms of Clinically Relevant Microorganisms , 2002, Infection Control & Hospital Epidemiology.

[50]  Michael H. Miller,et al.  Pharmacodynamics of Daptomycin in a Murine Thigh Model of Staphylococcus aureus Infection , 2001, Antimicrobial Agents and Chemotherapy.

[51]  R. Akins,et al.  Bactericidal Activities of Two Daptomycin Regimens against Clinical Strains of Glycopeptide Intermediate-ResistantStaphylococcus aureus, Vancomycin-ResistantEnterococcus faecium, and Methicillin-ResistantStaphylococcus aureus Isolates in an In Vitro Pharmacodynamic Model with Simulated Endocardial V , 2001, Antimicrobial Agents and Chemotherapy.

[52]  K. Regan,et al.  Once-Daily Dosing in Dogs Optimizes Daptomycin Safety , 2000, Antimicrobial Agents and Chemotherapy.

[53]  F. Tally,et al.  Development of daptomycin for gram-positive infections. , 2000, The Journal of antimicrobial chemotherapy.

[54]  G. Drusano,et al.  Daptomycin: a novel agent for Gram-positive infections. , 1999, Expert opinion on investigational drugs.

[55]  Y. Fukuchi,et al.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin , 1997, The Lancet.

[56]  F. Tenover,et al.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. , 1997, The Journal of antimicrobial chemotherapy.

[57]  B. R. Reddy,et al.  Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. , 1991, Annals of internal medicine.

[58]  K. Werdan,et al.  Mechanisms of infective endocarditis: pathogen–host interaction and risk states , 2014, Nature Reviews Cardiology.

[59]  Servicio de Angiología,et al.  Safety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy , 2012 .

[60]  Aseem Kumar,et al.  Impact of Vancomycin Exposure on Outcomes in Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia: Support for Consensus Guidelines Suggested Targets , 2012 .

[61]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[62]  N. Khardori.  Daptomycin Exposure and the Probability of Elevations in the Creatine Phosphokinase Level: Data from a Randomized Trial of Patients with Bacteremia and Endocarditis , 2010 .

[63]  M. Lichterfeld,et al.  High-dose daptomycin for the treatment of endocarditis caused by Staphylococcus aureus with intermediate susceptibility to glycopeptides. , 2010, International journal of antimicrobial agents.

[64]  B. Cunha,et al.  Methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE) in a patient with Job's syndrome (hyperimmunoglobulin E syndrome) successfully treated with linezolid and high-dose daptomycin. , 2008, Heart & lung : the journal of critical care.

[65]  A. Kumar,et al.  Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus , 2008 .

[66]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[67]  F. Tally,et al.  Leading article Development of daptomycin for Gram-positive infections , 2000 .